Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms Double-ITK-GVHc
- 07 Jul 2018 This trial has been completed in France, according to European Clinical Trials Database.
- 19 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 19 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.